1 / 1

Ipilimumab(Yervoy)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Not specified in the specification.

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

YERVOY (ipilimumab) is a recombinant, fully human monoclonal antibody that targets CTLA-4, a negative regulator of T-cell activation. By binding to CTLA-4, YERVOY enhances the immune system’s antitumor response through T-cell activation and proliferation. It is administered via intravenous infusion and has demonstrated clinical efficacy in multiple solid tumor malignancies when used alone or synergistically in combination with immune checkpoint inhibitors such as nivolumab.

Initially approved in 2011, YERVOY has since expanded its indications across various cancer types, including melanoma, RCC, CRC, HCC, and NSCLC. Its utility spans both first-line and adjuvant settings, with a particular focus on tumors characterized by high mutational burden or immune susceptibility. The combination with nivolumab enhances dual checkpoint blockade, promoting durable anti-tumor immunity. Dosing, safety, and administration specifics are regulated and require close adherence to clinical guidelines. Further pharmacologic details and long-term safety data are not specified in the specification.

Generic name

Ipilimumab(Yervoy)

English name

Ipilimumab

Alternative Names

Yervoy

Drug prices

Indications

YERVOY is indicated for the treatment of:

Melanoma:

Unresectable or metastatic melanoma in adults and pediatric patients ≥12 years (as monotherapy or combined with nivolumab).

Adjuvant treatment of cutaneous melanoma in adults after complete resection.

Renal Cell Carcinoma (RCC):

First-line treatment of intermediate/poor-risk advanced RCC in combination with nivolumab.

Colorectal Cancer (CRC):

Unresectable/metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) CRC in combination with nivolumab.

Hepatocellular Carcinoma (HCC):

First-line or post-sorafenib treatment of unresectable/metastatic HCC in combination with nivolumab.

Non-Small Cell Lung Cancer (NSCLC):

Metastatic NSCLC expressing PD-L1 (≥1%) or recurrent NSCLC (with/without platinum-doublet chemotherapy) in combination with nivolumab.

Malignant Pleural Mesothelioma:

First-line treatment in combination with nivolumab.

Esophageal Squamous Cell Carcinoma (ESCC):

First-line treatment of unresectable advanced/metastatic ESCC in combination with nivolumab.

Therapeutic Target

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)

Active Ingredients

Ipilimumab

Dosage form

INJECTION

specifications

Single-dose vials: 50 mg/10 mL (5 mg/mL). 200 mg/40 mL (5 mg/mL).

Description

50 mg/10 mL (5 mg/mL) clear to slightly opalescent, colorless to pale-yellow solution in a single-dose vial (NDC not specified).

Dosage and Administration

General Instructions:

Administer as an intravenous infusion over 30 minutes.

Diluent: 0.9% NaCl or 5% dextrose to a final concentration of 1–2 mg/mL.

Premedication: Not required unless managing infusion reactions.

CATEGORY NAVIGATION